|
Real world impact of treatment-induced peripheral neuropathy (TIPN) on patient reported outcomes (PROs) in patients with multiple myeloma (MM) in the United States. |
|
|
|
Consulting or Advisory Role - Genentech (Inst); GlaxoSmithKline (Inst); Onyx (Inst); Sanofi (Inst) |
Research Funding - Celgene (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Onyx (Inst); Sanofi (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Onyx |
Travel, Accommodations, Expenses - Onyx |
|
|
No Relationships to Disclose |
|
|
Employment - Vector Oncology |
Research Funding - Vector Oncology |